Resveratrol promotes proteasome-dependent degradation of Nanog via p53 activation and induces differentiation of glioma stem cells

Stem Cell Research

Volumn 11, Issue 1, 2013, Pages 601-610

  Sato, Atsushi ^a   Okada, Masashi ^a   Shibuya, Keita ^a,b   Watanabe, Eriko ^a,b   Seino, Shizuka ^a,b   Suzuki, Kaori ^a,b   Narita, Yoshitaka ^c   Shibui, Soichiro ^c   Kayama, Takamasa ^a   Kitanaka, Chifumi ^a,b  

^a YAMAGATA UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEASOME; PROTEIN P53; RESVERATROL; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NANOG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL POPULATION; CELL SURVIVAL; CLIOMA STEM CELL; CONTROLLED STUDY; DOWN REGULATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; LONG TERM CARE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; GENE SILENCING; GLIOMA; HOMEODOMAIN PROTEINS; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOPLASTIC STEM CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STILBENES; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877354623     PISSN: 18735061     EISSN: 18767753     Source Type: Journal    
DOI: 10.1016/j.scr.2013.04.004     Document Type: Article

References (49)

1. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004, 24:2783-2840.
2. Athar M., Back J.H., Tang X., Kim K.H., Kopelovich L., Bickers D.R., Kim A.L. Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 2007, 224:274-283.
3. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
4. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov. 2006, 5:493-506.
5. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res. (Phila.) 2009, 2:409-418.
6. Bleau A.M., Hambardzumyan D., Ozawa T., Fomchenko E.I., Huse J.T., Brennan C.W., Holland E.C. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4:226-235.
7. Boyer L.A., Lee T.I., Cole M.F., Johnstone S.E., Levine S.S., Zucker J.P., Guenther M.G., Kumar R.M., Murray H.L., Jenner R.G., Gifford D.K., Melton D.A., Jaenisch R., Young R.A. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005, 122:947-956.
8. Dick J.E. Stem cell concepts renew cancer research. Blood 2008, 112:4793-4807.
9. Frank N.Y., Schatton T., Frank M.H. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest. 2010, 120:41-50.
10. Hemmati H.D., Nakano I., Lazareff J.A., Masterman-Smith M., Geschwind D.H., Bronner-Fraser M., Kornblum H.I. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15178-15183.
11. Hong H., Takahashi K., Ichisaka T., Aoi T., Kanagawa O., Nakagawa M., Okita K., Yamanaka S. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009, 460:1132-1135.
12. Ikushima H., Todo T., Ino Y., Takahashi M., Miyazawa K., Miyazono K. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 2009, 5:504-514.
13. Lee J., Son M.J., Woolard K., Donin N.M., Li A., Cheng C.H., Kotliarova S., Kotliarov Y., Walling J., Ahn S., Kim M., Totonchy M., Cusack T., Ene C., Ma H., Su Q., Zenklusen J.C., Zhang W., Maric D., Fine H.A. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008, 13:69-80.
14. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., Hilsenbeck S.G., Pavlick A., Zhang X., Chamness G.C., Wong H., Rosen J., Chang J.C. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 2008, 100:672-679.
15. Lin T., Chao C., Saito S., Mazur S.J., Murphy M.E., Appella E., Xu Y. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat. Cell Biol. 2005, 7:165-171.
16. + cancer stem cells in glioblastoma. Mol. Cancer 2006, 5:67.
17. Matsuda K., Sato A., Okada M., Shibuya K., Seino S., Suzuki K., Watanabe E., Narita Y., Shibui S., Kayama T., Kitanaka C. Targeting JNK for therapeutic depletion of stem-like glioblastoma cells. Sci. Rep. 2012, 2:516.
18. Mitsui K., Tokuzawa Y., Itoh H., Segawa K., Murakami M., Takahashi K., Maruyama M., Maeda M., Yamanaka S. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 2003, 113:631-642.
19. Pan G., Thomson J.A. Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell Res. 2007, 17:42-49.
20. Pandey P.R., Okuda H., Watabe M., Pai S.K., Liu W., Kobayashi A., Xing F., Fukuda K., Hirota S., Sugai T., Wakabayashi G., Koeda K., Kashiwaba M., Suzuki K., Chiba T., Endo M., Fujioka T., Tanji S., Mo Y.Y., Cao D., Wilber A.C., Watabe K. Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res. Treat. 2011, 130:387-398.
21. Park D.M., Rich J.N. Biology of glioma cancer stem cells. Mol. Cells 2009, 28:7-12.
22. Penuelas S., Anido J., Prieto-Sanchez R.M., Folch G., Barba I., Cuartas I., Garcia-Dorado D., Poca M.A., Sahuquillo J., Baselga J., Seoane J. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009, 15:315-327.
23. Piccirillo S.G., Reynolds B.A., Zanetti N., Lamorte G., Binda E., Broggi G., Brem H., Olivi A., Dimeco F., Vescovi A.L. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006, 444:761-765.
24. Ramakrishna S., Suresh B., Lim K.H., Cha B.H., Lee S.H., Kim K.S., Baek K.H. PEST motif sequence regulating human Nanog for proteasomal degradation. Stem Cells Dev. 2011, 20:1511-1519.
25. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
26. Rich J.N., Bao S. Chemotherapy and cancer stem cells. Cell Stem Cell 2007, 1:353-355.
27. Sato A., Sakurada K., Kumabe T., Sasajima T., Beppu T., Asano K., Ohkuma H., Ogawa A., Mizoi K., Tominaga T., Kitanaka C., Kayama T. Association of stem cell marker CD133 expression with dissemination of glioblastomas. Neurosurg. Rev. 2010, 33:175-183. (discussion 183-174).
28. Sato A., Sunayama J., Matsuda K., Seino S., Suzuki K., Watanabe E., Tachibana K., Tomiyama A., Kayama T., Kitanaka C. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis. Stem Cells 2011, 29:1942-1951.
29. Sato A., Sunayama J., Okada M., Watanabe E., Seino S., Shibuya K., Suzuki K., Narita Y., Shibui S., Kayama T., Kitanaka C. Glioma-initiating cell elimination by metformin activation of FoxO3 via AMPK. Stem Cells Transl. Med. 2012, 1:811-824.
30. She Q.B., Bode A.M., Ma W.Y., Chen N.Y., Dong Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res. 2001, 61:1604-1610.
31. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
32. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
33. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
34. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A.A., Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G., Mirimanoff R.O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10:459-466.
35. Sunayama J., Matsuda K., Sato A., Tachibana K., Suzuki K., Narita Y., Shibui S., Sakurada K., Kayama T., Tomiyama A., Kitanaka C. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 2010, 28:1930-1939.
36. Sunayama J., Sato A., Matsuda K., Tachibana K., Suzuki K., Narita Y., Shibui S., Sakurada K., Kayama T., Tomiyama A., Kitanaka C. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro Oncol. 2010, 12:1205-1219.
37. Sunayama J., Sato A., Matsuda K., Tachibana K., Watanabe E., Seino S., Suzuki K., Narita Y., Shibui S., Sakurada K., Kayama T., Tomiyama A., Kitanaka C. FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity. Stem Cells 2011, 29:1327-1337.
38. Tcgar N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
39. Todaro M., Alea M.P., Di Stefano A.B., Cammareri P., Vermeulen L., Iovino F., Tripodo C., Russo A., Gulotta G., Medema J.P., Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1:389-402.
40. Tyagi A., Gu M., Takahata T., Frederick B., Agarwal C., Siriwardana S., Agarwal R., Sclafani R.A. Resveratrol selectively induces DNA damage, independent of Smad4 expression, in its efficacy against human head and neck squamous cell carcinoma. Clin. Cancer Res. 2011, 17:5402-5411.
41. Wang J., Sun Q., Morita Y., Jiang H., Gross A., Lechel A., Hildner K., Guachalla L.M., Gompf A., Hartmann D., Schambach A., Wuestefeld T., Dauch D., Schrezenmeier H., Hofmann W.K., Nakauchi H., Ju Z., Kestler H.A., Zender L., Rudolph K.L. A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. Cell 2012, 148:1001-1014.
42. Wen P.Y., Kesari S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359:492-507.
43. Woodard J., Joshi S., Viollet B., Hay N., Platanias L.C. AMPK as a therapeutic target in renal cell carcinoma. Cancer Biol. Ther. 2010, 10:1168-1177.
44. Wurdak H., Zhu S., Romero A., Lorger M., Watson J., Chiang C.Y., Zhang J., Natu V.S., Lairson L.L., Walker J.R., Trussell C.M., Harsh G.R., Vogel H., Felding-Habermann B., Orth A.P., Miraglia L.J., Rines D.R., Skirboll S.L., Schultz P.G. An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. Cell Stem Cell 2010, 6:37-47.
45. Yang Y.P., Chang Y.L., Huang P.I., Chiou G.Y., Tseng L.M., Chiou S.H., Chen M.H., Chen M.T., Shih Y.H., Chang C.H., Hsu C.C., Ma H.I., Wang C.T., Tsai L.L., Yu C.C., Chang C.J. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. J. Cell. Physiol. 2012, 227:976-993.
46. Zbinden M., Duquet A., Lorente-Trigos A., Ngwabyt S.N., Borges I., Ruiz i Altaba A. Nanog regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J. 2010, 29:2659-2674.
47. Zhang M., Behbod F., Atkinson R.L., Landis M.D., Kittrell F., Edwards D., Medina D., Tsimelzon A., Hilsenbeck S., Green J.E., Michalowska A.M., Rosen J.M. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 2008, 68:4674-4682.
48. Zheng H., Ying H., Wiedemeyer R., Yan H., Quayle S.N., Ivanova E.V., Paik J.H., Zhang H., Xiao Y., Perry S.R., Hu J., Vinjamoori A., Gan B., Sahin E., Chheda M.G., Brennan C., Wang Y.A., Hahn W.C., Chin L., DePinho R.A. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell 2010, 17:497-509.
49. Zhou B.B., Zhang H., Damelin M., Geles K.G., Grindley J.C., Dirks P.B. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 2009, 8:806-823.